Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Jacob

Showing results (811-820 of 911) with videos related to

Pageof 92
Sort By:
American Journal of Hematology|December 30, 2016
Thrombospondin-1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemiaSeethal A Jacob, Enrico M Novelli, Jeffrey S Isenberg, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 26, 2022
Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNPWilliam W Busse, Andrew Wellman, Zuzana Diamant, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Response to TherapyBartolome R Celli, Stephanie Christenson, Klaus F Rabe, et al.
The Journal of Allergy and Clinical Immunology|November 16, 2025
Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthmaIan D Pavord, Njira L Lugogo, Mario Castro, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1982
The metabolism of avermectins B1a, H2B1a, and H2B1b by liver microsomesG T Miwa, J S Walsh, W J VandenHeuvel, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|August 6, 2025
Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthmaWilliam W Busse, Monica Kraft, Christian Domingo, et al.
Advances in Therapy|December 9, 2024
Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryNjira L Lugogo, Xavier Soler, Yasuhiro Gon, et al.
The American Journal of Psychiatry|April 19, 2023
Cerebral Small Vessel Disease Progression and the Risk of Dementia: A 14-Year Follow-Up StudyMina A Jacob, Mengfei Cai, Vera van de Donk, et al.
Allergy|July 28, 2022
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthmaAlberto Papi, Jonathan Corren, Mario Castro, et al.
ERJ Open Research|October 20, 2023
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthmaJonathan Corren, Constance H Katelaris, Mario Castro, et al.
Pageof 92

Showing results (811-820 of 911) with videos related to

Sort By:
Pageof 92
American Journal of Hematology|December 30, 2016
Thrombospondin-1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemiaSeethal A Jacob, Enrico M Novelli, Jeffrey S Isenberg, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 26, 2022
Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNPWilliam W Busse, Andrew Wellman, Zuzana Diamant, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Response to TherapyBartolome R Celli, Stephanie Christenson, Klaus F Rabe, et al.
The Journal of Allergy and Clinical Immunology|November 16, 2025
Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthmaIan D Pavord, Njira L Lugogo, Mario Castro, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1982
The metabolism of avermectins B1a, H2B1a, and H2B1b by liver microsomesG T Miwa, J S Walsh, W J VandenHeuvel, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|August 6, 2025
Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthmaWilliam W Busse, Monica Kraft, Christian Domingo, et al.
Advances in Therapy|December 9, 2024
Baseline Characteristics of Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryNjira L Lugogo, Xavier Soler, Yasuhiro Gon, et al.
The American Journal of Psychiatry|April 19, 2023
Cerebral Small Vessel Disease Progression and the Risk of Dementia: A 14-Year Follow-Up StudyMina A Jacob, Mengfei Cai, Vera van de Donk, et al.
Allergy|July 28, 2022
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthmaAlberto Papi, Jonathan Corren, Mario Castro, et al.
ERJ Open Research|October 20, 2023
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthmaJonathan Corren, Constance H Katelaris, Mario Castro, et al.
Pageof 92